



Published in final edited form as:

Diabetes Obes Metab. 2018 May ; 20(5): 1302–1305. doi:10.1111/dom.13202.

Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial

Jeremy Pettus¹, Dominic Reeds², Tricia Santos Cavaiola¹, Schafer Boeder¹, Michelle Levin¹, Gary Tobin², Edda Cava², Dung Thai^{3,4}, Jim Shi^{3,4}, Hai Yan^{3,4}, Edgar Bautista³, John McMillan³, Roger Unger⁵, Robert R. Henry¹, and Samuel Klein²

¹Department of Medicine, University of California San Diego, San Diego, CA,

²Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO,

³REMD Biotherapeutics, Camarillo, CA,

⁴Beijing Cosci-REMD, Beijing, China,

⁵Touchstone Diabetes Center, University of Texas Southwestern, Dallas TX

Abstract

The aim of the current study was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycemic control and insulin use were evaluated during outpatient and inpatient settings, before and after, a single 70-mg dose of REMD-477 (half-life 7–10 days) or placebo. Inpatient insulin use was 26% (95% CI:47%,4%) lower 1 day after dosing with REMD-477 than placebo ($p=0.02$). Continuous glucose monitoring during post-treatment days 6–12 showed average daily glucose was 27 mg/dl lower ($p<0.001$), percent time-in-target-range (70–180 mg/dl) was ~25% greater (~3.5 hours/day) ($p=0.001$), and percent time-in-hyperglycemic-range (>180 mg/dl) was ~40% lower (~4 hours/day) ($p=0.001$) in the REMD-477 than the placebo group, without a difference in percent time-in-hypoglycemic-range (<70 mg/dl). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycemic control in patients with type 1 diabetes.

Keywords

insulin; glucose homeostasis; glycemic control diabetes

Send correspondence to: Samuel Klein, MD. Center for Human Nutrition, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8031, St Louis, MO 63110, Phone: (314) 362-8708, Fax: (314) 362-8230, sklein@wustl.edu.

Conflict of Interest Statement

J. Pettus, D. Reeds, R. Henry, R. Unger and S. Klein are receiving research support from REMD Biotherapeutics for other studies. S. Klein and J. Pettus have served as consultants to REMD Biotherapeutics. None of the other authors have any conflicts of interest relevant to this manuscript.

INTRODUCTION

Type 1 diabetes is caused by an immune-mediated destruction of insulin-producing pancreatic β -cells, making patients completely dependent on exogenous insulin for survival. However, therapy with insulin, insulin analogues, and insulin pumps cannot match the β -cell's regulated control of insulin release. Therefore, most patients with type 1 diabetes do not achieve the recommended goal for glycemic control [1], and often experience large swings in blood glucose concentrations and iatrogenic hypoglycemia [2] [3].

The absence of insulin secretion from β -cells in patients with type 1 diabetes affects the paracrine regulation of juxtaposed α -cells [4], which causes an increase in basal glucagon secretion and a paradoxical increase in the glucagon response to postprandial hyperglycemia [5] [6]. These increases in plasma glucagon stimulate hepatic glucose production and complicate glycemic control [7] [8]. The importance of glucagon in the pathophysiology of type 1 diabetes has been demonstrated in rodent models, which have shown total β -cell destruction fails to induce diabetes in glucagon receptor knockout mice [4], and glucagon receptor blockade normalizes plasma glucose without exogenous insulin in streptozotocin-induced diabetes [9].

The purpose of the present study was to evaluate the therapeutic potential of glucagon blockade in patients with type 1 diabetes, by conducting a proof-of-concept, randomized, double-blind, placebo-controlled trial to assess the effect of REMD 477, a human IgG2 monoclonal antibody against the human glucagon receptor, on insulin requirements and glycemic control.

METHODS

Twenty-one men and women with type 1 diabetes were randomized to either REMD 477 (n=10) or placebo (n=11) (Supplemental Table 1). Eligibility criteria included: i) 18–60 years old; ii) BMI 18.5–30.0 kg/m²; iii) treatment with insulin infusion pump; iv) C-peptide <0.2 ng/mL; v) HbA1c \leq 6.0% and <9.0%; vi) no severe hypoglycemic events in the last 6 months; and vii) serum alanine aminotransferase (ALT) <1.5x upper limit of normal. All participants provided informed consent before participating in this study.

All participants monitored their blood glucose concentrations by using CGM (DexCom G4, Dexcom, San Diego, CA) and insulin use for 2 weeks before the intervention to assess baseline glycemic control. Participants were then admitted to the Clinical Research Unit (CRU) for 5 days. Meals comprised of 50% calories as carbohydrate, 35% as fat and 15% as protein were provided at 0800h, 1300h and 1800h, and a snack at 2100h to provide total daily energy requirements calculated as 1.3 times estimated resting energy expenditure [10]. Plasma glucose was monitored every 1–2 h throughout admission, and targeted blood glucose concentrations (90–120 mg/dL postabsorptive and <180 mg/dL up to 2 h postprandial) were maintained by intravenous insulin infusion. After the 24-h baseline evaluation, insulin infusion was decreased to allow plasma glucose to increase to 250–300 mg/dL for 16 h (from 2400h on day 1 until 1600h on day 2) to decrease the effect of intra-islet insulin concentrations on glucagon secretion. At 0800h on day 2, participants received a

subcutaneous injection of placebo or REMD-477 (70 mg; REMD Biotherapeutics, Camarillo, CA). This dose (~1 mg/kg) was chosen because it was shown to decrease fasting blood glucose without adverse effects in a study conducted in healthy volunteers (unpublished observations). After discharge, participants were seen weekly for 8 weeks for medical monitoring, review of CGM data, and adjustment of insulin therapy to obtain optimal glycemic control.

The primary outcome was the effect of single dose of REMD-477, which has a 7–10 day half-life, on 24-h insulin requirements during inpatient day 4 compared with day 1. Secondary outcomes were the effects of REMD-477 on the percent time CGM glucose was in target-range (70–180 mg/dL), hyperglycemic-range (>180 mg/dL) and hypoglycemic-range (< 70 mg/dL), daily average CGM glucose, and 24-h insulin use. Safety and tolerability, including changes in standard blood tests, lipid profile, liver biochemistries, and serum amylase, lipase and glucagon, were assessed.

Differences in outcome measures between the REMD-477 and placebo treatments were evaluated by using repeated measures analysis of covariance with treatment as the fixed effect (REMD-477 vs. placebo), study day fitted as a repeated measure as the within-subject effect, and the pre-treatment values as covariate. Model assumptions were reviewed prior to fitting. The least squares means for either treatment on each study day along with its difference (REMD-477 - placebo), 95% confidence interval, and p-values were evaluated. It was estimated that 8 subjects in each group would be sufficient to detect a 30% reduction in insulin requirements with a power of 0.9 and an alpha value of 0.05. Therefore, a minimum of 10 subjects were recruited in each group to account for an estimated 20% drop-out rate.

RESULTS

No participant withdrew from the study or missed any study visits. The amount of insulin needed to maintain plasma glucose targets on inpatient day 4 (24–48 h after treatment with either placebo or REMD-477) compared with the amount needed on inpatient day 1 (baseline) decreased by 14% (7.3 units) in the REMD-477 group, but increased by 12% (4.8 units) in the placebo group ($p=0.02$) (Figure 1A). During post-treatment days 6–12, average daily CGM glucose concentration was 27 mg/dl lower (95% CI: 15, 40; $p<0.001$), without a significant difference in daily insulin dose (Figure 1B). The percent time-in-target range (70–180 mg/dl) was ~25% greater (~3.5 hours/day) ($p=0.001$), and the percent time-in-hyperglycemic range (>180 mg/dl) was ~40% lower (~4 hours/day) ($p=0.001$) in the REMD-477 than the placebo group (Figure 1C). Percent time-in-hypoglycemic range (<70mg/dl) during post-treatment days 6–12 was not different from baseline and was not different between groups (Figure 1C).

The most common AEs in the REMD-477 group were headaches and oropharyngeal pain that resolved within 2 and 8 days, respectively, without treatment (Supplemental Table 2). Mean serum ALT increased but remained within the normal range in the REMD-477 group, and did not increase above twice the upper limit of normal in any subject at any time point. Fasting plasma glucagon increased from 20.2 to 56.3 pmol/L, 2 weeks after REMD-477

treatment ($p=0.01$) and returned to baseline by 8 weeks. No changes in body weight, blood pressure, heart rate or plasma lipid profile were detected in either group.

CONCLUSIONS

This proof-of-concept, randomized, placebo-controlled trial evaluated the effect of REMD-477, a human IgG2 monoclonal antibody against the human glucagon receptor, on insulin requirements and glycemic control in patients with type 1 diabetes. We found a single dose of REMD-477 decreased insulin requirements and improved glycemic control, without an increase in hypoglycemia or adverse events. These data support the notion that glucagon is involved in the pathophysiology of type 1 diabetes, and demonstrate the potential of glucagon receptor blockade as a novel therapeutic approach for this patient population.

A series of studies have evaluated the effect of glucagon receptor blockade in people by using small molecule antagonists, antisense oligonucleotide inhibitors of the glucagon receptor and monoclonal glucagon receptor antibodies [11]. All of these approaches have consistently improved glycemic control, manifested by a decrease in A1c and blood glucose concentrations. However, several adverse effects of therapy have also been reported, including an increase in blood pressure, weight, plasma LDL-cholesterol and plasma transaminase concentrations [11]. While not measured with other compounds, a recent publication showed an increase in hepatic fat content with LY2409021, which was the first to correlate the transaminase increase with potential, underlying pathophysiology [12]. An additional concern is that chronic glucagon receptor blockade will cause pancreatic α -cell hyperplasia, which has been shown by in animal models [13, 14] and in case reports demonstrating α -cell hypertrophy and severe hyperglucagonemia (without evidence of glucagonoma syndrome) in people with loss-of-function glucagon receptor mutations [14, 15]. Our study is the only published study we are aware of to assess the use of glucagon receptor blockade in people with type 1 diabetes, and it is possible that adverse effects with glucagon antagonism will differ between type 1 and type 2 diabetes. However, the type 1 population has a unique need for additional therapies given they are completely dependent on exogenous insulin, often experience large swings in blood glucose, and often have inadequate overall glycemic control. Although we did not detect any serious adverse effects of REMD-477 therapy in our participants, the design of our study, which involved only a single injection of drug, is not able to adequately evaluate potential side effects of long-term therapy.

The results of the present study demonstrate the potential efficacy of glucagon receptor blockade as an adjunctive therapy in patients with type 1 diabetes. Additional studies are needed to determine the optimal dose and dosing schedule for maximum insulin-sparing and glucoregulatory effects, while fully evaluating the adverse effects of long-term therapy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by REMD Biotherapeutics, Camarillo, CA. The authors thank Karen Flavin, and the staff of the Clinical Research Units at Washington University School of Medicine and the University of California San Diego for their help in conducting the studies, and the study subjects for their participation.

References

- [1]. Clements MA, Foster NC, Maahs DM, et al. Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. *Pediatr Diabetes*. 2015:
- [2]. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. *Diabetes*. 2010; 59: 2333–2339 [PubMed: 20876723]
- [3]. McCrimmon RJ, Frier BM. Hypoglycaemia, the most feared complication of insulin therapy. *Diabetes Metab*. 1994; 20: 503–512 [PubMed: 7713272]
- [4]. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *J Clin Invest*. 2012; 122: 4–12 [PubMed: 22214853]
- [5]. Davidson JA, Holland WL, Roth MG, et al. Glucagon therapeutics: Dawn of a new era for diabetes care. *Diabetes Metab Res Rev*. 2016; 32: 660–665 [PubMed: 26729301]
- [6]. Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. *Diabetes*. 2006; 55: 2318–2323 [PubMed: 16873696]
- [7]. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. *Metabolism*. 2002; 51: 636–641 [PubMed: 11979398]
- [8]. Asmar M, Tangaa W, Madsbad S, et al. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. *Am J Physiol Endocrinol Metab*. 2010; 298: E614–621 [PubMed: 19996386]
- [9]. Wang MY, Yan H, Shi Z, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. *Proc Natl Acad Sci U S A*. 2015; 112: 2503–2508 [PubMed: 25675519]
- [10]. Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr*. 1990; 51: 241–247 [PubMed: 2305711]
- [11]. Nunez DJ, D'Alessio D. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). *Diabetes Obes Metab*. 2017:
- [12]. Guzman CB, Zhang XM, Liu R, et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017; 19: 1521–1528 [PubMed: 28371155]
- [13]. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. *Proc Natl Acad Sci U S A*. 2003; 100: 1438–1443 [PubMed: 12552113]
- [14]. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. *Pancreas*. 2009; 38: 941–946 [PubMed: 19657311]
- [15]. Langer E, Wewer Albrechtsen NJ, Hansen LH, et al. Pancreatic alpha-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. *Endocrinol Diabetes Metab Case Rep*. 2016; 2016:




Figure 1.

Percent change in insulin use one day after treatment (Day 4) with either placebo (white bar) or REMD-477 (black bar) relative to baseline (Day 1) during the inpatient study (A), average daily glucose concentration, assessed by continuous glucose monitoring (CGM), during a 2-week outpatient baseline (white bars) and Days 6 to 12 (black bars) after treatment with either placebo or REMD-477 (B), and percent time CGM glucose in target (70–180 mg/dL) (white bars), hyperglycemic (>180 mg/dL) (black bars), and hypoglycemic (<70 mg/dL) (gray bars) ranges during a 2-week outpatient baseline and during post-treatment Days 6 to 12. Value significantly different from placebo value, *p=0.021, †p<0.001. Value significantly different from baseline value, ‡p=0.001. Data are LS means ±SE.